CD276 and glioblastoma: An emerging CAR T cell therapy target is B7-H3 (B7 homologue 3 protein, also known as CD276), which is a novel co-stimulatory molecule that modulates immune responses.438,439 Several clinical trials are recruiting to evaluate the effectiveness of B7-H3-CAR T cell therapy in recurrent glioblastoma patients (NCT05241392, NCT05474378, NCT04077866, NCT04385173, NCT05366179).